Aurora Cannabis posted fiscal Q1 2027 net revenue of C$67.6 million, down 9% year over year.
Net loss from continuing operations narrowed to C$4 million; adjusted EBITDA (non-GAAP) fell to C$3.4 million from C$10.8 million.
Adjusted gross margin before fair value adjustments (non-GAAP) slipped 6 percentage points to 58%.
International medical cannabis net revenue rose 17% to C$43.3 million, while Canadian medical cannabis net revenue fell 25% to C$20.7 million on lower reimbursement rates.
Cash, cash equivalents and short-term investments totaled C$149.1 million with no debt; management expects Q2 revenue and adjusted EBITDA to rise sequentially.
ACB•
